These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 15383188)

  • 21. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.
    Reaven G; Segal K; Hauptman J; Boldrin M; Lucas C
    Am J Cardiol; 2001 Apr; 87(7):827-31. PubMed ID: 11274935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
    Jacob S; Rabbia M; Meier MK; Hauptman J
    Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
    Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
    JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
    Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
    Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orlistat and cardiovascular risk profile in hypertensive patients with metabolic syndrome: the ARCOS study.
    Zanella MT; Uehara MH; Ribeiro AB; Bertolami M; Falsetti AC; Yunes MA
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):368-76. PubMed ID: 16767303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of weight loss with or without orlistat treatment on adipocytokines, inflammation, and oxidative markers in obese women.
    Bougoulia M; Triantos A; Koliakos G
    Hormones (Athens); 2006; 5(4):259-69. PubMed ID: 17178701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of orlistat therapy on serum insulin level and morphological and functional parameters of peripheral arterial circulation in obese patients].
    Hajduković Z; Jovelić A; Zivotić-Vanović M; Raden S
    Vojnosanit Pregl; 2005 Nov; 62(11):803-10. PubMed ID: 16375203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.
    Shi YF; Pan CY; Hill J; Gao Y
    Diabet Med; 2005 Dec; 22(12):1737-43. PubMed ID: 16401321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
    Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Endocr J; 2010; 57(9):777-86. PubMed ID: 20683173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials.
    Hutton B; Fergusson D
    Am J Clin Nutr; 2004 Dec; 80(6):1461-8. PubMed ID: 15585756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
    Nakou ES; Filippatos TD; Georgoula M; Kiortsis DN; Tselepis AD; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2008 Jul; 24(7):1919-29. PubMed ID: 18513463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
    Aldekhail NM; Logue J; McLoone P; Morrison DS
    Obes Rev; 2015 Dec; 16(12):1071-80. PubMed ID: 26345590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
    Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
    Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orlistat use in overweight women with mild hypercholesterolemia.
    Petrogiannopoulos C; Kalogeropoulos S; Latsios GS; Hartzoulakis G; Kalogeropoulos G; Zaharof A
    Int J Clin Pharmacol Res; 2002; 22(3-4):85-8. PubMed ID: 12837045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
    Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M;
    Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The use of orlistat in the treatment of obesity, dyslipidaemia and Type 2 diabetes.
    Nelson RH; Miles JM
    Expert Opin Pharmacother; 2005 Nov; 6(14):2483-91. PubMed ID: 16259579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.